156 related articles for article (PubMed ID: 18058468)
21. Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome.
Willeke P; Gaubitz M; Schotte H; Maaser C; Domschke W; Schlüter B; Becker H
Arthritis Res Ther; 2007; 9(2):R43. PubMed ID: 17470266
[TBL] [Abstract][Full Text] [Related]
22. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
[TBL] [Abstract][Full Text] [Related]
23. [Serum markers in breast cancer and colorectal cancer (1997)].
Bellet D; Mlika-Cabanne N; Bedenne L; Brun B; Demeaux JL; Legrand JL; Lorimier G; Mignotte H; Ollivier JM; Piperno-Neumann S; Rinaldi Y; Rousset H; Rymer JC; Laversin S
Gynecol Obstet Fertil; 2001 Jan; 29(1):62-3. PubMed ID: 11217195
[No Abstract] [Full Text] [Related]
24. [Relationship between macrophage migration inhibitory factor and cardiac function in patients with congestive heart failure].
Liu Y; Yu XY; Lin QX; Yang M; Shan ZX; Zheng M
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1169-70. PubMed ID: 14625178
[TBL] [Abstract][Full Text] [Related]
25. Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis.
Bargagli E; Olivieri C; Nikiforakis N; Cintorino M; Magi B; Perari MG; Vagaggini C; Spina D; Prasse A; Rottoli P
Respir Physiol Neurobiol; 2009 Jul; 167(3):261-7. PubMed ID: 19464392
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.
Camlica H; Duranyildiz D; Oguz H; Oral EN; Yasasever V
Pathol Oncol Res; 2008 Mar; 14(1):79-83. PubMed ID: 18347935
[TBL] [Abstract][Full Text] [Related]
27. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
28. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease.
Hoshina T; Kusuhara K; Ikeda K; Mizuno Y; Saito M; Hara T
Scand J Rheumatol; 2008; 37(6):445-9. PubMed ID: 18720262
[TBL] [Abstract][Full Text] [Related]
29. Presence of villin, a tissue-specific cytoskeletal protein, in sera of patients and an initial clinical evaluation of its value for the diagnosis and follow-up of colorectal cancers.
Dudouet B; Jacob L; Beuzeboc P; Magdelenat H; Robine S; Chapuis Y; Christoforov B; Cremer GA; Pouillard P; Bonnichon P
Cancer Res; 1990 Jan; 50(2):438-43. PubMed ID: 2295083
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two lymphokines (macrophage migration inhibition, leukocyte adherence inhibition factors) and carcinoembryonic antigen, in colorectal cancer and colonic premalignant lesions.
Shkolnik T; Livni E; Reshef R; Lachter J; Eidelman S
Am J Gastroenterol; 1987 Dec; 82(12):1275-8. PubMed ID: 3318403
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
33. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
34. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis.
Kitaichi N; Kotake S; Sasamoto Y; Namba K; Matsuda A; Ogasawara K; Onoé K; Matsuda H; Nishihira J
Invest Ophthalmol Vis Sci; 1999 Jan; 40(1):247-50. PubMed ID: 9888451
[TBL] [Abstract][Full Text] [Related]
35. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
36. Serum macrophage migration inhibitory factor (MIF) in the intercritical phase of hereditary periodic fevers and its relationship with the MIF-173G/C polymorphism.
Rigante D; Flex A; Federico G; Pola R; Candelli M; Manna R; Pugliese AL; Cerquaglia C; Compagnone A; Stabile A
Scand J Rheumatol; 2007; 36(4):307-10. PubMed ID: 17763209
[TBL] [Abstract][Full Text] [Related]
37. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
38. Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF).
Aloisi AM; Pari G; Ceccarelli I; Vecchi I; Ietta F; Lodi L; Paulesu L
Pain; 2005 May; 115(1-2):142-51. PubMed ID: 15836977
[TBL] [Abstract][Full Text] [Related]
39. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
Japink D; Leers MP; Sosef MN; Nap M
Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]